Active Pharmacovigilance in Peruvian Population: Surveillance of a Timolol/Brimonidine/Dorzolamide Ophthalmic Fixed Combination
Homero Contreras-Salinas,1 Mariana Barajas-Hernández,1 Leopoldo Martín Baiza-Durán,1 Alan Omar Vázquez-Álvarez,2 Manuel Alejandro Bautista-Castro,1 Lourdes Yolotzin Rodríguez-Herrera1 1Pharmacovigilance Department, Laboratorios Sophia...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-02-01
|
Series: | Clinical Ophthalmology |
Subjects: | |
Online Access: | https://www.dovepress.com/active-pharmacovigilance-in-peruvian-population-surveillance-of-a-timo-peer-reviewed-article-OPTH |
id |
doaj-0461246abb8d42d18a83b40487dc3999 |
---|---|
record_format |
Article |
spelling |
doaj-0461246abb8d42d18a83b40487dc39992021-02-17T01:13:59ZengDove Medical PressClinical Ophthalmology1177-54832021-02-01Volume 1558359062170Active Pharmacovigilance in Peruvian Population: Surveillance of a Timolol/Brimonidine/Dorzolamide Ophthalmic Fixed CombinationContreras-Salinas HBarajas-Hernández MBaiza-Durán LMVázquez-Álvarez AOBautista-Castro MARodríguez-Herrera LYHomero Contreras-Salinas,1 Mariana Barajas-Hernández,1 Leopoldo Martín Baiza-Durán,1 Alan Omar Vázquez-Álvarez,2 Manuel Alejandro Bautista-Castro,1 Lourdes Yolotzin Rodríguez-Herrera1 1Pharmacovigilance Department, Laboratorios Sophia, S.A. de C.V, Zapopan, Jalisco, México; 2School of Medicine and Health Science, Tecnológico de Monterrey, Guadalajara, Jalisco, MéxicoCorrespondence: Lourdes Yolotzin Rodríguez-Herrera Tel +52 3001 4200 ext 1188Email lourdes.rodriguez@sophia.com.mxPurpose: In this study active pharmacovigilance was used in an uncontrolled population to enrich the safety profile and canvass the Adverse Drug Reactions (ADRs) associated with the use of a fixed combination of 0.5% timolol + 0.2% brimonidine + 2.0% dorzolamide (TBD).Methods: Active pharmacovigilance consisting of 3 follow-up calls within 60 days was used to monitor the product’s safety and identify new risks by searching for unexpected ADRs and increased incidence, tolerability, drug interactions and special population-related ADRs.Results: Ninety-four ADRs were reported by a total of 246 patients (0.38 ADRs/patient); all of them were classified as “mild”. We found an increased risk of ADRs with a Relative Risk (RR) for simultaneous use of TBD + ophthalmic ciprofloxacin and TBD + oral atorvastatin; 2.0309 (95% CI, 1.2467– 3.3083) and 1.8864 (95% CI, 1.0543– 3.3754), respectively. Two unexpected ADRs were discovered, both of which presented belonged to the System Organ Class (SOC) of “infections and infestations” and the preferred term (PT) of “nasopharyngitis.”.Conclusion: Three safety signals were identified, two of them corresponded to an increase in the incidence of ADRs and the last one is associated with 2 unexpected ADR. Nevertheless, we found a good tolerability profile for TBD in the study population.Keywords: adverse drug reactions, active pharmacovigilance, surveillance, glaucoma, timolol/brimonidine/dorzolamidehttps://www.dovepress.com/active-pharmacovigilance-in-peruvian-population-surveillance-of-a-timo-peer-reviewed-article-OPTHadverse drug reactionsactive pharmacovigilancesurveillanceglaucomatimolol/brimonidine/dorzolamide. |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Contreras-Salinas H Barajas-Hernández M Baiza-Durán LM Vázquez-Álvarez AO Bautista-Castro MA Rodríguez-Herrera LY |
spellingShingle |
Contreras-Salinas H Barajas-Hernández M Baiza-Durán LM Vázquez-Álvarez AO Bautista-Castro MA Rodríguez-Herrera LY Active Pharmacovigilance in Peruvian Population: Surveillance of a Timolol/Brimonidine/Dorzolamide Ophthalmic Fixed Combination Clinical Ophthalmology adverse drug reactions active pharmacovigilance surveillance glaucoma timolol/brimonidine/dorzolamide. |
author_facet |
Contreras-Salinas H Barajas-Hernández M Baiza-Durán LM Vázquez-Álvarez AO Bautista-Castro MA Rodríguez-Herrera LY |
author_sort |
Contreras-Salinas H |
title |
Active Pharmacovigilance in Peruvian Population: Surveillance of a Timolol/Brimonidine/Dorzolamide Ophthalmic Fixed Combination |
title_short |
Active Pharmacovigilance in Peruvian Population: Surveillance of a Timolol/Brimonidine/Dorzolamide Ophthalmic Fixed Combination |
title_full |
Active Pharmacovigilance in Peruvian Population: Surveillance of a Timolol/Brimonidine/Dorzolamide Ophthalmic Fixed Combination |
title_fullStr |
Active Pharmacovigilance in Peruvian Population: Surveillance of a Timolol/Brimonidine/Dorzolamide Ophthalmic Fixed Combination |
title_full_unstemmed |
Active Pharmacovigilance in Peruvian Population: Surveillance of a Timolol/Brimonidine/Dorzolamide Ophthalmic Fixed Combination |
title_sort |
active pharmacovigilance in peruvian population: surveillance of a timolol/brimonidine/dorzolamide ophthalmic fixed combination |
publisher |
Dove Medical Press |
series |
Clinical Ophthalmology |
issn |
1177-5483 |
publishDate |
2021-02-01 |
description |
Homero Contreras-Salinas,1 Mariana Barajas-Hernández,1 Leopoldo Martín Baiza-Durán,1 Alan Omar Vázquez-Álvarez,2 Manuel Alejandro Bautista-Castro,1 Lourdes Yolotzin Rodríguez-Herrera1 1Pharmacovigilance Department, Laboratorios Sophia, S.A. de C.V, Zapopan, Jalisco, México; 2School of Medicine and Health Science, Tecnológico de Monterrey, Guadalajara, Jalisco, MéxicoCorrespondence: Lourdes Yolotzin Rodríguez-Herrera Tel +52 3001 4200 ext 1188Email lourdes.rodriguez@sophia.com.mxPurpose: In this study active pharmacovigilance was used in an uncontrolled population to enrich the safety profile and canvass the Adverse Drug Reactions (ADRs) associated with the use of a fixed combination of 0.5% timolol + 0.2% brimonidine + 2.0% dorzolamide (TBD).Methods: Active pharmacovigilance consisting of 3 follow-up calls within 60 days was used to monitor the product’s safety and identify new risks by searching for unexpected ADRs and increased incidence, tolerability, drug interactions and special population-related ADRs.Results: Ninety-four ADRs were reported by a total of 246 patients (0.38 ADRs/patient); all of them were classified as “mild”. We found an increased risk of ADRs with a Relative Risk (RR) for simultaneous use of TBD + ophthalmic ciprofloxacin and TBD + oral atorvastatin; 2.0309 (95% CI, 1.2467– 3.3083) and 1.8864 (95% CI, 1.0543– 3.3754), respectively. Two unexpected ADRs were discovered, both of which presented belonged to the System Organ Class (SOC) of “infections and infestations” and the preferred term (PT) of “nasopharyngitis.”.Conclusion: Three safety signals were identified, two of them corresponded to an increase in the incidence of ADRs and the last one is associated with 2 unexpected ADR. Nevertheless, we found a good tolerability profile for TBD in the study population.Keywords: adverse drug reactions, active pharmacovigilance, surveillance, glaucoma, timolol/brimonidine/dorzolamide |
topic |
adverse drug reactions active pharmacovigilance surveillance glaucoma timolol/brimonidine/dorzolamide. |
url |
https://www.dovepress.com/active-pharmacovigilance-in-peruvian-population-surveillance-of-a-timo-peer-reviewed-article-OPTH |
work_keys_str_mv |
AT contrerassalinash activepharmacovigilanceinperuvianpopulationsurveillanceofatimololbrimonidinedorzolamideophthalmicfixedcombination AT barajashernandezm activepharmacovigilanceinperuvianpopulationsurveillanceofatimololbrimonidinedorzolamideophthalmicfixedcombination AT baizaduranlm activepharmacovigilanceinperuvianpopulationsurveillanceofatimololbrimonidinedorzolamideophthalmicfixedcombination AT vazquezalvarezao activepharmacovigilanceinperuvianpopulationsurveillanceofatimololbrimonidinedorzolamideophthalmicfixedcombination AT bautistacastroma activepharmacovigilanceinperuvianpopulationsurveillanceofatimololbrimonidinedorzolamideophthalmicfixedcombination AT rodriguezherreraly activepharmacovigilanceinperuvianpopulationsurveillanceofatimololbrimonidinedorzolamideophthalmicfixedcombination |
_version_ |
1724265635012149248 |